In addition, our analysis has shown that LDH and S100, which are already implemented as laboratory characteristics to monitor melanoma patients, are significantly elevated in the high-CCL20 patient group (p = 0.004 and p = 0.049, respectively). Here, CCL20 is linked to melanoma.